China Shineway Pharmaceutical Group Ltd
HKEX:2877
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Shineway Pharmaceutical Group Ltd
Revenue
China Shineway Pharmaceutical Group Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Shineway Pharmaceutical Group Ltd
HKEX:2877
|
Revenue
¥3.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥15B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥32.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥41.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Revenue
¥22.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
China Shineway Pharmaceutical Group Ltd
Glance View
In the bustling world of pharmaceuticals, China Shineway Pharmaceutical Group Ltd. stands as a noteworthy player adeptly navigating the intricate channels of traditional Chinese medicine and modern pharmaceutical practices. Established in 1996, the company has rooted its foundation in the age-old wisdom of Chinese herbal medicine, while seamlessly integrating contemporary manufacturing methods. Headquartered in the industrial city of Shijiazhuang, Shineway has grown into one of China's top pharmaceutical enterprises, distinguished by its commitment to quality and innovation in healthcare solutions. At the heart of Shineway's operations is a robust production line that focuses on the development and distribution of herbal-based medicines, granules, and injections that cater to a diverse array of health needs, ranging from respiratory ailments to cardiovascular conditions. Shineway's journey to profitability hinges on a well-crafted strategy of combining the trusted efficacy of traditional Chinese cures with rigorous scientific validation and modern production processes. With a comprehensive distribution network spanning domestic markets and cautiously expanding international borders, the company has managed to effectively channel its products through hospitals, clinics, and retail pharmacies. Their financial success is further bolstered by substantial investments in technology and research, allowing Shineway to continuously refine its offerings and maintain competitive prices. In an era where the global health landscape is constantly evolving, China Shineway Pharmaceutical Group Ltd. thrives by striking a delicate balance between preserving traditional medicinal heritage and embracing the advancements of contemporary pharmaceutical sciences, thereby securing a steady revenue stream while fostering broader acceptance of traditional Chinese medicine across the globe.
See Also
What is China Shineway Pharmaceutical Group Ltd's Revenue?
Revenue
3.1B
CNY
Based on the financial report for Dec 31, 2025, China Shineway Pharmaceutical Group Ltd's Revenue amounts to 3.1B CNY.
What is China Shineway Pharmaceutical Group Ltd's Revenue growth rate?
Revenue CAGR 10Y
4%
Over the last year, the Revenue growth was -17%. The average annual Revenue growth rates for China Shineway Pharmaceutical Group Ltd have been -7% over the past three years , 3% over the past five years , and 4% over the past ten years .